Technology

Platform Technology Introduction

Next-generation bio-conjugate Technology platform

SelecAll™

Site-specific bioconjugation technology

Albubody™

Albumin Affibody-Inserted Antibody Fragment

Unnatural amino acid incorporation technology

Conventional TechnologyLysine Conjugation

Random conjugation results in structural deformation in protein

Decreased protein activity

Difficulty in manufacturing homogenous drugs

Complicated purification process

Our TechnologySite-specific Bioconjugation

Site-specific conjugation minimizes deformation of protein structure

Maintains protein activity

Allows manufacturing of homogenous drugs

Simple purification process

UAA (Unnatural amino acid) containing click chemistry reactive handle

IEDDA is the fastest click chemistry reaction, which involves the reaction between tetrazine and trans-cyclooctene (TCO) The rapid and efficient formation of a covalent bond between two molecules under mild and biocompatible conditions Unnatural amino acids are used to introduce new chemical and physical properties to proteins.

Engineered orthogonal pair of tRNA
/ aminoacyl tRNA synthetase

Orthogonal pair of Methanococcus jannaschii tyrosyl-tRNA synthetase (MjTyrRS) and its cognate suppressor tRNA (MjtRNATyrCUA) has been developed for UAA incorporation into proteins.

IEDDA click chemistry reaction

Therapeutic drug
incorporated unnatural amino acids

Linker-Albumin

Rapid reaction through click chemistry(IEDDA) High safety due to site-specific incorporation of unnatural amino acid High conjugation yield achieved through fast reaction and enable simple manufacturing process

Drug-Albumin Conjugate

Evolution of bioconjugation technology

  • Recombinant Protein

    Very short half-life

    · Protein from genetic recombination technology
    · Short half-life in vivo
    · Decreased stability in vivo

  • Fusion Protein

    Short half-life,
    Non-site-specific

    · Expressed as fusion partner protein
    · Unable to site-specifically conjugate drugs
    · Potential risks in immunogenicity
    · Potential side effects due to high dose administration following decreased activity

  • PEGylation

    Achieve certain half-life extension

    · Increase stability by random conjugation of PEG polymers
    · Decreased activity due to PEG
    · Potential immunogenicity due to PEG

  • Fc Conjugation

    Risks of side effects

    · Long-acting drugs by conjugation with Fc region
    · Application limited to certain drug moiety due to non-specific conjugation
    · Decreased manufacturing yield and difficulties in CMC management due to non-specific conjugation
    · Potential side effects due to FC region

  • SelecAll™ Technology

    Increase half-life and minimize side-effects

    · Development of long-acting drugs by conjugating albumin into a specific site
    · Minimize reduction of drug activity
    · Increase half-life and minimize side effects
    · High production yield and simple CMC management
R
e
c
o
m
b
i
n
a
n
t

P
r
o
t
e
i
n
F
u
s
i
o
n

P
r
o
t
e
i
n
P
E
G
y
l
a
t
i
o
n
F
c

C
o
n
j
u
g
a
t
i
o
n
S
e
l
e
c
A
l
l
™

T
e
c
h
n
o
l
o
g
y

  • Very short half-life

    · Protein from genetic recombination technology
    · Short half-life in vivo
    · Decreased stability in vivo

  • Short half-life, Non-site-specific

    · Expressed as fusion partner protein
    · Unable to site-specifically conjugate drugs
    · Potential risks in immunogenicity
    · Potential side effects due to high dose administration following decreased activity

  • Achieve certain half-life extension

    · Increase stability by random conjugation of PEG polymers
    · Decreased activity due to PEG
    · Potential immunogenicity due to PEG

  • Risks of side effects

    · Long-acting drugs by conjugation with Fc region
    · Application limited to certain drug moiety due to non-specific conjugation
    · Decreased manufacturing yield and difficulties in CMC management due to non-specific conjugation
    · Potential side effects due to FC region

  • Increase half-life and minimize side-effects

    · Development of long-acting drugs by conjugating albumin into a specific site
    · Minimize reduction of drug activity
    · Increase half-life and minimize side effects
    · High production yield and simple CMC management

Convential bioconjugation techniques

Random conjugation results in structural deformation in protein Decreased protein activity Difficulty in manufacturing homogenous drugs Complicated purification process

Site-specific Bioconjugation techniques

Site-specific covalent conjugation retains original protein structure and biological activity, leading to high conjugation yields (>90%) with homogeneous drug preparation

KOR